Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (381-390 of 910) with videos related to

Pageof 91
Sort By:
American Heart Journal|March 12, 2011
High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaborationSanneke P M de Boer, Elizabeth H Barnes, Cynthia M Westerhout, et al.
Journal of the American College of Cardiology|October 3, 2003
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximabChristophe L Dubois, Ann Belmans, Christopher B Granger, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
American Heart Journal|January 25, 2008
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromesSunil V Rao, Padma R Kaul, Lawrence Liao, et al.
JAMA|May 3, 2007
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006Keith A A Fox, Philippe Gabriel Steg, Kim A Eagle, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
European Heart Journal|March 17, 2010
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary EventsJosé López-Sendón, Enrique P Gurfinkel, Esteban Lopez de Sa, et al.
American Heart Journal|January 28, 2010
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trialRudolf Jarai, Kurt Huber, Kris Bogaerts, et al.
European Heart Journal|January 4, 2014
Large streamlined trials in cardiovascular diseaseGonzalo Calvo, John J V McMurray, Christopher B Granger, et al.
The American Journal of Medicine|November 11, 2017
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE TrialMeena P Rao, Dragos Vinereanu, Daniel M Wojdyla, et al.
Pageof 91

Showing results (381-390 of 910) with videos related to

Sort By:
Pageof 91
American Heart Journal|March 12, 2011
High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaborationSanneke P M de Boer, Elizabeth H Barnes, Cynthia M Westerhout, et al.
Journal of the American College of Cardiology|October 3, 2003
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximabChristophe L Dubois, Ann Belmans, Christopher B Granger, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
American Heart Journal|January 25, 2008
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromesSunil V Rao, Padma R Kaul, Lawrence Liao, et al.
JAMA|May 3, 2007
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006Keith A A Fox, Philippe Gabriel Steg, Kim A Eagle, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
European Heart Journal|March 17, 2010
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary EventsJosé López-Sendón, Enrique P Gurfinkel, Esteban Lopez de Sa, et al.
American Heart Journal|January 28, 2010
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trialRudolf Jarai, Kurt Huber, Kris Bogaerts, et al.
European Heart Journal|January 4, 2014
Large streamlined trials in cardiovascular diseaseGonzalo Calvo, John J V McMurray, Christopher B Granger, et al.
The American Journal of Medicine|November 11, 2017
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE TrialMeena P Rao, Dragos Vinereanu, Daniel M Wojdyla, et al.
Pageof 91